DOCSLIB.ORG

Orphan Medical, Inc. (ORPH - $9.70) January 21, 2003 Initiating Coverage – Aggressive Growth STRONG BUY

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Orphan Medical, Inc. (ORPH - $9.70) January 21, 2003 Initiating Coverage – Aggressive Growth STRONG BUY Ernest W. Andberg, CFA [email protected] (612) 492-8836 Specialty Pharmaceuticals Orphan Medical, Inc. (ORPH - $9.70) January 21, 2003 Initiating Coverage – Aggressive Growth STRONG BUY Financial Summary Key Points: S Rev (mil) 2001 2002E 2003E Initiating coverage with a STRONG BUY recommendation and a 9-12 month price target of $22.50. Mar $2.3 $3.7A $4.0 S Key drug launch underway – Xyrem® was approved by the FDA in July 2002 and Jun $2.4 $3.5A $6.0 Sep $2.9 $4.2A $7.5 launched in early October. The drug is the only currently approved treatment for Dec $3.6 $4.5 $8.5 cataplexy, a debilitating disease that has an immediate market potential approaching $125 million in the U. S. FY $11.3 $15.9 $26.0 S Existing product portfolio continues to show surprising strength with growth of P/Sales 8.9x 6.3x 3.9x nearly 40% in fiscal 2002. S EPS 2001 2002 2003E High Gross Margin Model – We expect Orphan to generate gross margins in the mid 85% range, or higher. Mar ($0.19) ($0.11) ($0.44) S Jun ($0.23) ($0.16) ($0.30) Tax Sheltered Earnings – Tax loss carry forwards should shelter earnings over the Sep ($0.24) ($0.42) ($0.19) next four to five years. Dec ($0.14) ($0.42) ($0.11) S Favorable risk reward ratio – In our opinion, the approval of Xyrem has significantly FY ($0.80) ($1.11) ($1.03) reduced the risk of current investments in Orphan’s shares while the upside potential P/E nm nm nm remains substantial. Investment Recommendation: Orphan Medical, Inc. is an emerging specialty pharmaceutical company on the verge of a Price: $9.70 significant expansion of revenues due to the FDA approval and commercial introduction of Xyrem. Xyrem is the only approved treatment for cataplexy, a debilitating disease that has a 52-Week Range: $15.00-5.95 Target: $22.50 market potential approaching $125 million in the U. S. In our opinion, Xyrem will help push Rating: STRONG BUY revenues from approximately $16 million in fiscal 2002 to between $65 to $70 million in fiscal 2005 and produce a rapidly growing, profitable bottom line beginning in the 2004 time Shares Outstanding: 10.4 mil frame. Float: 10.0 mil Mrk. Capitalization: $101 mil Ave. Volume: 35,000 At the current time, we continue to believe that the market is undervaluing the existing Instit. Ownership: 33% portfolio of drugs and the very real upside potential of Xyrem. Assuming our revenue and BV / Share $1.18 earnings estimates for fiscal 2003 through 2005 are reasonable, we believe the shares have Debt / Tot. Cap.: 0% upside potential into the $20- $25 range over the next twelve months. Our target price Est. LT EPS Growth: 50% assumes a terminal multiple of forty times our fiscal 2005 tax adjusted earnings per share Exp. Next Rpt. Date: 1/30/03 discounted at 25% plus a discounted value of the tax loss carryforwards. We are initiating coverage of the stock with a STRONG BUY rating for aggressive investors. Company Description Orphan Medical acquires, develops, and markets pharmaceuticals of high medical value for inadequately treated and uncommon diseases. The Company serves three therapeutic areas that are characterized by well-defined patient populations and served by physician specialists: antidotes, oncology support and sleep disorders. Source: Reuters. Feltl and Company Research Department. Please see important disclosures at end of report. 120 South Sixth Street, Suite 2600 Minneapolis, MN 55402 1-866-655-3431 Investment Overview Orphan Medical is an emerging, specialty pharmaceutical company focused on developing and marketing treatments for uncommon or inadequately treated diseases. The Company was originally established as a division of Chronimed, Inc. to explore and commercialize orphan drugs as defined in the Orphan Drug Act of 1983. This Act provides incentives to companies to develop and market drugs for diseases or conditions that are known to affect fewer than 200,000 people in the United States. The Company became a publicly traded entity when it was spun out of Chronimed in 1994. Today, Orphan’s efforts are targeted at three principal, therapeutic areas; oncology support, antidotes and sleep disorders. Each of these is characterized by a well-defined patient population and treated by an easily identified group of medical specialists. Orphan believes this focus allows a targeted marketing approach that makes a large sales force unnecessary because efforts can be focused on a limited number of medical specialists or patients. Orphan currently has six FDA approved drugs in the market. These include Busulfex® Injection, Antizol® Injection, Sucraid® oral solution, Cystadane®, Elliots B® Solution and Xyrem® (sodium oxybate) oral solution. For all intents and purposes, Orphan looks like a virtual drug company. While the Company has a dedicated sales force to market it products, it conducts no in-house clinical research, and does no manufacturing or distribution. The Company does not conduct basic research and does not attempt to discover new drugs. To expand the pipeline, the Company normally seeks to acquire products that are already in Phase II or Phase III clinical trials, or in an earlier stage with proof of concept established. Clinical research is managed by in-house staff, but contracted out to independent research organizations. Manufacturing is likewise contracted out to third party contract manufacturers and distribution is done through third- party pharmacy benefit management and specialty pharmacy services firms. Xyrem Appoval The U. S. Food and Drug Administration (FDA) approved Xyrem on July 17, 2002 and the drug was launched in early October. Xyrem is the first drug approved specifically for the treatment of cataplexy. Cataplexy is a debilitating symptom of narcolepsy usually triggered by strong emotions such as, laughter, anger, or surprise. Cataplexy sufferers often have fragmented sleep. In its most severe form cataplexy can cause a person to collapse during waking hours. The approval of Xyrem represents the single most important catalyst in the Company’s history. In our opinion, Xyrem will prove to be a commercial success that will produce a rapidly growing revenue stream and lead to significant profitability over the next three to five years. The Market Narcolepsy is a chronic neurological disorder that usually appears in patients in their mid- teens or early twenties. The disease is most often recognized by its primary symptom, excessive daytime sleepiness (EDS), which disrupts normal activities during the day. Additional symptoms include cataplexy, fragmented nighttime sleep, hypnagogic hallucinations (vivid and sometimes frightening dreams when falling asleep or waking up), and sleep paralysis (brief periods of feeling muscle paralysis upon waking). Because narcolepsy is a rare disease and is not easy to diagnose, the total population of potential sufferers is difficult to define precisely, but most observers believe the disease affects approximately 150,000 persons in the United States about half of whom are diagnosed. Between 60-90 percent of narcolepsy patients are believed to also suffer cataplexy. Currently, there are approximately 25,000 cataplexy patients being treated off label with antidepressants (tricyclic and selective serotonin reuptake inhibitors). These drugs have limited efficacy and often produce unsatisfactory side effects. In addition, patients build up tolerance to these drugs over time. Initially Xyrem will target this universe of patients. Based Page 2 Orphan Medical, Inc. 01/21/03 on the initial pricing of Xyrem, this represents a potential market of approximately $125 million in the U. S. ORPH is currently conducting a Phase III(b) clinical trial with Xyrem for the treatment of EDS associated with narcolepsy. The trial is designed to evaluate the effectiveness of Xyrem, in combination with stimulant drugs, in reducing the incidence of EDS in narcolepsy patients. EDS has traditionally been treated with stimulants like Ritalin and Provigil, but these drugs do not treat cataplexy. Earlier trials have shown a statistically significant reduction in EDS when Xyrem was used in combination with stimulants. However, since this was not the primary endpoint of these trials the Company initiated the current Phase III(b) trial. ORPH expects to complete enrollment in this study by the middle of this year and if the earlier trials are born out, intends to file a supplemental NDA in 2004. Assuming a positive outcome and approval by the FDA, the total market potential for Xyrem could then be in the range of $300 to $400 million in the U.S. Marketing and Distribution The active ingredient in Xyrem is sodium oxybate – the sodium salt of gamma hydroxybutyrate (GHB). GHB is a naturally occurring chemical found in the brain and other tissues. It was first synthesized in 1960 and was found to have sedative and anesthetic properties, but was supplanted by more effective anesthetic agents. In the early 1990’s, GHB was marketed as a dietary supplement for enhancing athletic performance, primarily among body builders, and became a “street” drug of abuse often described as a date-rape drug because of its sedative and anesthetic effects. As a consequence, the FDA and a number of states intervened to prohibit the manufacture or use of GHB. In early 2000, a bill was passed and signed into law making GHB a controlled, Schedule I substance, similar to LSD or heroin. This is the most restrictive designation of the Controlled Substances Act. At the same time Xyrem received a Subpart H exemption and will be designated as a Schedule III drug, meaning it cannot be sold, distributed, or provided to anyone except by prescription. As a consequence, ORPH and the FDA have worked to design a comprehensive risk management program for Xyrem. The program includes distribution through a single centralized pharmacy, physician and patient education programs, creation of a patient and physician registry and detailed patient surveillance.
Load more

Recommended publications
  • An Empirical Review of Major Legislation Affecting Drug Development: Past Experiences, Effects, and Unintended Consequences
    THE MILBANK QUARTERLY A MULTIDISCIPLINARY JOURNAL OF POPULATION HEALTH AND HEALTH POLICY An Empirical Review of Major Legislation Affecting Drug Development: Past Experiences, Effects, and Unintended Consequences AARON S. KESSELHEIM Brigham and Women’s Hospital; Harvard Medical School Context: With the development of transformative drugs at a low point, numer- ous commentators have recommended new legislation that uses supplementary market exclusivity as an incentive to promote innovation in the pharmaceutical market. Methods: This report provides an historical perspective on proposals for encour- aging drug research. Four legislative programs have been primarily designed to offer market exclusivity to promote public health goals in the pharmaceutical or biomedical sciences: the Bayh-Dole Act of 1980, the Orphan Drug Act of 1983, the Hatch-Waxman Act of 1984, and the pediatric exclusivity provisions of the FDA Modernization Act of 1997. I reviewed quantitative and qualitative studies that reported on the outcomes from these programs and evaluated the quality of evidence generated. Findings: All four legislative programs generally have been regarded as success- ful, although such conclusions are largely based on straightforward descriptive reports rather than on more rigorous comparative data or analyses that suffi- ciently account for confounding. Overall, solid data demonstrate that market exclusivity incentives can attract interest from parties involved in drug de- velopment. However, using market exclusivity to promote innovation in the pharmaceutical market can be prone to misuse, leading to improper gains. In addition, important collateral effects have emerged with substantial negative public health implications. Conclusions: Using market exclusivity to promote pharmaceutical innovation can lead to positive outcomes, but the practice is also characterized by waste Address correspondence to: Aaron S.
    [Show full text]
  • Regulatory and Ethical Issues for Orphan Medicines
    UNIVERSIDADE DE COIMBRA REGULATORY AND ETHICALISSUESFORORPHANMEDICINES REGULATORY Dissertação de Mestrado em Tecnologias do Medicamento, orientadapeloProfessorDoutorJoãoJoséSousaepela doMedicamento, Dissertação deMestradoemTecnologias Professora Doutora Maria Eugénia Pina e apresentada à Faculdade de Farmácia daUniversidadedeCoimbra deFarmácia Professora DoutoraMariaEugéniaPinaeapresentadaàFaculdade Maria Luísa Borges BatistaBouwman Maria LuísaBorges Junho de2016 Regulatory and Ethical Issues for Orphan Medicines Maria Luísa Borges Batista Bouwman Mestrado em Tecnologias do Medicamento Prof. Doutor João José Sousa Prof.ª Doutora Maria Eugénia Pina Junho de 2016 Universidade de Coimbra When it is obvious that the goals cannot be reached, don´t adjust the goals, adjust the action steps Confucius ii Acknowledgements I would like to thank to my mentors, Professor João José Sousa and Professor Maria Eugénia Pina, for accepting me as their student, knowing very little about my academic past. But also by their ready availability, their incentives and for the contribution with suggestions for improvement. Special thanks to Pedro for the constant support, big patience and for the precious informatic help. To my parents who always supported my dreams, who helped me in my academic travel and giving me strength in many difficult times. Thank you! Agradecimentos Aos meus orientadores, Professor Doutor João José Sousa e Professora Doutora Maria Eugénia Pina, por me terem aceitado como Orientanda, mesmo sabendo muito pouco sobre o meu percurso académico. Mas também pela disponibilidade que sempre demonstraram, pelos incentivos e pela contribuição com sugestões de melhoria. Ao Pedro pelo apoio constante, pela enorme paciência, e pela preciosa ajuda informática. Aos meus pais que apoiaram sempre os meus sonhos, que me ajudaram nesta minha longa caminhada no mundo académico e me deram força nos momentos mais difíceis.
    [Show full text]
  • Incentivizing the Utilization of Pharmacogenomics in Drug Development Valerie Gutmann Koch
    Journal of Health Care Law and Policy Volume 15 | Issue 2 Article 3 Incentivizing the Utilization of Pharmacogenomics in Drug Development Valerie Gutmann Koch Follow this and additional works at: http://digitalcommons.law.umaryland.edu/jhclp Part of the Chemicals and Drugs Commons, and the Health Law Commons Recommended Citation Valerie G. Koch, Incentivizing the Utilization of Pharmacogenomics in Drug Development, 15 J. Health Care L. & Pol'y 263 (2012). Available at: http://digitalcommons.law.umaryland.edu/jhclp/vol15/iss2/3 This Article is brought to you for free and open access by DigitalCommons@UM Carey Law. It has been accepted for inclusion in Journal of Health Care Law and Policy by an authorized administrator of DigitalCommons@UM Carey Law. For more information, please contact [email protected]. INCENTIVIZING THE UTILIZATION OF PHARMACOGENOMICS IN DRUG DEVELOPMENT VALERIE GUTMANN KOCH* I. INTRODUCTION The last decades have witnessed remarkable advancements in the fields of genetics and genomics, highlighted by the successful completion of the map of the human genome in 2003.' With this achievement came scientific possibilities that, only a few decades earlier, seemed more science fiction than reality. Of these developments, pharmacogenomics is hailed by many as a panacea for problems associated with pharmaceutical drug use and development.2 The Human Genome Project (HGP) and associated research have demonstrated that all human beings share 99.9 percent of their DNA. 3 Pharmacogenomics focuses on the 0.1 percent differences between individuals and promises to allow physicians to tailor a patient's prescription according to his or her genetic profile, reducing painful and sometimes deadly side effects, ensuring appropriate dosage decisions, and targeting specific disease pathways.4 Copyright © 2012 by Valerie Gutmann Koch.
    [Show full text]
  • The Orphan Drug Act
    The Orphan Drug Act The Orphan Drug Act: Its Implementation and Impact on Rare Disease Patient by Venkatesh Burla Thesis Submitted to the College of Health and Human Services Eastern Michigan University in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE in Clinical Research Administration Thesis Committee: Irwin G. Martin, PhD, Chair Stephen A. Sonstein, PhD March 2013 Ypsilanti, Michigan The Orphan Drug Act Dedication This thesis is dedicated to my loving brother-in-law, Nagaraju Minda, who encouraged and motivated me all the time to complete this thesis. I also dedicate this thesis to my parents, who made my dreams come true with their immense support and hard work in helping me to complete my master’s. I am grateful to have you as my parents. ii The Orphan Drug Act Acknowledgements First and foremost, praise and thanks to the God, the Almighty, for His showers of blessings throughout my research work to complete the thesis successfully. I would have never been able to finish my dissertation without the guidance of my mentor, thesis chair Dr. Irwin Martin, Associate Prof at Eastern Michigan University. I would like to express my deepest gratitude to him for his excellent guidance, caring, patience, and providing me with an excellent atmosphere for doing research. Dr. Martin has been the ideal supervisor and the motivation for my research work. His dynamism, vision, sincerity, and motivation have deeply inspired me. Without his advice and persistent help, this thesis would not have been possible. This gratitude extends to my thesis committee member and my academic advisor, Dr.
    [Show full text]
  • Orphan Drug Development: Incentives Under the Orphan Drug Act
    Trinity College Trinity College Digital Repository Senior Theses and Projects Student Scholarship Spring 2015 Orphan Drug Development: Incentives Under the Orphan Drug Act Sara H D Smith Trinity College, [email protected] Follow this and additional works at: https://digitalrepository.trincoll.edu/theses Part of the Business Law, Public Responsibility, and Ethics Commons, Food and Drug Law Commons, Intellectual Property Law Commons, Law and Economics Commons, and the Pharmacoeconomics and Pharmaceutical Economics Commons Recommended Citation Smith, Sara H D, "Orphan Drug Development: Incentives Under the Orphan Drug Act". Senior Theses, Trinity College, Hartford, CT 2015. Trinity College Digital Repository, https://digitalrepository.trincoll.edu/theses/486 ORPHAN DRUG DEVELOPMENT: INCENTIVES UNDER THE ORPHAN DRUG ACT By Sara H D Smith A Thesis Submitted to the Department of Economics of Trinity College in Partial Fulfillment of the Requirements for the Bachelor of Arts Degree Economics 498-99 04/09/15 ABSTRACT After describing the intellectual property and regulatory environment for orphan drugs in the United States, this thesis compares the investment decisions in the orphan drug market with the larger pharmaceutical industry. A series of case studies trace the development paths of different orphan products using information collected through the Food and Drug Administration (FDA) Approved Drug Product and Orphan Drug Product Designation Databases. In addition to this analysis, difference-in-differences estimates calculated using annual revenues compare the relative success of different orphan products under the current incentive system. This study finds that partial orphan drugs are associated with larger revenue growth. Lastly, this study proposes several policy prescriptions as alternatives to the current legislation.
    [Show full text]
  • Evaluatepharma® Orphan Drug Report 2017
    EvaluatePharma® Orphan Drug Report 2017 4th Edition – February 2017 Welcome to the EvaluatePharma® Orphan Drug Report 2017 The fourth edition of EvaluatePharma’s Orphan Drug Report brings together many of our analyses to provide top-level insight, from the world’s financial markets, into the expected performance of the orphan drug market between now and 2022. Based on EvaluatePharma’s coverage of over 5,000 of the world’s leading pharmaceutical and biotech companies, the Orphan Drug Report 2017 highlights trends in prescription sales for orphan vs. non-orphan drugs, USA revenue per patient, orphan designation analysis in USA, Europe and Japan, product and company performance and the most valuable orphan drugs in development. Additional copies are available at: www.evaluategroup.com/orphandrug2017 2 EvaluatePharma® Orphan Drug Report 2017 Copyright © 2017 Evaluate Ltd. All rights reserved. Overview An orphan drug is a pharmaceutical product aimed at rare diseases or disorders. The development of orphan drugs has been financially incentivised through US law via the Orphan Drug Act of 1983. The National Organization for Rare Disorders (NORD), which was instrumental in establishing the Act, currently estimates 30 million Americans suffer from 7,000 rare diseases. Prior to the 1983 Act, 38 orphan drugs were approved. The success of the original Orphan Drug Act in the US led to it being adopted in other key markets, most notably in Japan in 1993 and in the European Union in 2000. Rare Disease Patient Populations are Defined in Law as: • USA: <200,000 patients (<6.37 in 10,000, based on US population of 314m) • EU: <5 in 10,000 (<250,000 patients, based on EU population of 514m) • Japan: <50,000 patients (<4 in 10,000 based on Japan population of 128m) Financial Incentives by Law Include: Market Exclusivity • USA: 7 Years of marketing exclusivity from approval; Note: Majority of orphan drugs have a compound patent beyond 7 years.
    [Show full text]
  • Redesigning the Orphan Drug Act: Examining the Government’S Use of Subsidy and Exclusivity for Incentivizing Drug Development
    Redesigning the Orphan Drug Act: Examining the Government’s Use of Subsidy and Exclusivity for Incentivizing Drug Development Molly Jordan Advisors: Professors Brian Baisa and Jun Ishii May 5, 2016 Submitted to the Department of Economics of Amherst College in partial fulfillment of the requirements for the degree of Bachelor of Arts with honors Acknowledgments I thank Professor Brian Baisa and Professor Jun Ishii for their invaluable guidance as advisors to this project. Without their expertise and patience, my thesis would not have been possible. I thank Professor Jessica Reyes for her guidance during the thesis seminar, as well as for serving as my major advisor ever since I took her Health Economics and Policy class freshman year. I thank the entire Economics Department for the thoughtful questions and comments that helped direct my thesis, as well as for playing a central and meaningful role in my Amherst education. I thank my fellow thesis writers, particularly Jason, for creating an inspiring and helpful academic community. I thank my roommates for being the best of friends and for tolerating my odd hours. I thank Becca and Devin for their constant support throughout this process. Finally, I thank my parents for their love and unwavering confidence in me. 1 Abstract The Orphan Drug Act incentivizes the development of drugs for rare diseases using R&D subsidies and years of market exclusivity. My thesis examines how the government can improve upon the social welfare generated by the orphan drug industry with a more refined distribution of these two incentive tools. I find that incentivizing drugs with subsidy instead of exclusivity optimizes the social benefit offered by the drugs, because subsidy incentivizes drug development without generating any of the deadweight loss that is created by monopoly pricing during exclusivity.
    [Show full text]
  • Rare Diseases, When Taken Together, Are Are Together, When Taken Diseases, Rare to According at All
    2013 MEDICINES IN DEVELOPMENT REPORT Rare Diseases A Report on Orphan Drugs in the Pipeline PRESENTED BY AMERICA’s biopharmACEUTICAL RESEARCH COMPANIES More Than 450 Medicines in Development for Rare Diseases Rare diseases, when taken together, are A major area of this research targets Orphan Drugs in Development* not that rare at all. In fact, according to rare cancers, accounting for more than Application the National Institutes of Health (NIH), one-third of all rare disease medicines in Submitted 30 million Americans have one of the development. Other top research areas Phase III nearly 7,000 diseases that are officially include genetic disorders, neurologi- Phase II deemed “rare” because alone they each cal conditions, infectious diseases and Phase I affect fewer than 200,000 people in autoimmune disorders. the United States. Sometimes, only Despite some recent victories, research a few hundred patients are known to 105 into treatments for rare diseases is a have a particular rare disease. daunting quest. This ongoing innovation Simply receiving a diagnosis of a rare and the hundreds of new medicines in disease often becomes a frustrating development now offer hope that physi- 85 quest, since many doctors may have nev- cians will have new treatment options er before heard of or seen the disease. for patients confronting a rare disease. This is, however, a time of great progress and hope. Biopharmaceutical 65 Contents research is entering an exciting new era Innovative Orphan Drugs with a growing understanding of the in the Pipeline ......................................... 2 human genome. Scientific advances have given researchers new tools to Orphan Drug Approvals ...........................4 explore rare diseases, which are often Challenges in Clinical Trials ......................6 more complex than common diseases.
    [Show full text]
  • Orphan Drug Utilization and Pricing Patterns (2012 - 2014) DATA BRIEF
    Orphan Drug Utilization and Pricing Patterns (2012 - 2014) DATA BRIEF OCTOBER 2016 KEY TAKEAWAYS A sample of 45 orphan drugs available between 2012 and 2014 shows almost half of these drugs’ usage—44 percent— was for non-orphan diseases. Across the three years of the study, on average 20 percent of orphan drug use was for non-orphan, on-label uses; while 24 percent was for off-label use. Drugs having little-to- no orphan utilization increased their prices by 42% during the three-year study period; while, those orphan drugs used almost exclusively to treat orphan diseases increased prices by only 15%. We also found that drugs having little-to-no off-label use increased their prices by only 16%; however, those drugs used extensively off-label increased their prices by 52% from 2012-2014. Orphan Drug Utilization and P ricing Patterns (2012-2014) Summary Orphan drugs- developed to treat rare diseases affecting patient populations of fewer than 200,000 people annually - have become a lucrative business opportunity for drug makers. These medications made up almost half of all new drugs approved by the U.S. Food and Drug Administration (FDA) in 2015 Given the growing number of orphan drugs currently in the market as well as the pipeline of future orphan treatments, understanding the utilization and pricing patterns of orphan drugs is of increasing interest to policymakers, public, and private payers given the potential cost impacts on the healthcare system. This study finds that price changes of certain orphan medications appear to be tied to the degree and type of utilization of the drug.
    [Show full text]
  • Evaluatepharma® Orphan Drug Report 2015
    EvaluatePharma® Orphan Drug Report 2015 3rd Edition – October 2015 Welcome to the EvaluatePharma® Orphan Drug Report 2015 The third edition of EvaluatePharma’s Orphan Drug Report brings together many of our analyses to provide top-level insight, from the world’s financial markets, into the expected performance of the orphan drug market between now and 2020. Based on EvaluatePharma’s coverage of over 5,000 of the world’s leading pharmaceutical and biotech companies, the Orphan Drug Report 2015 highlights trends in prescription sales for orphan vs. non- orphan drugs, orphan designation analysis in the USA and Europe, product and company performance, phase III R&D spend and return on investment. Additional copies are available at: www.evaluategroup.com/orphandrug2015 About EvaluatePharma Since 1996 EvaluatePharma has been providing senior decision makers within the pharmaceutical industry with an essential service that models the sector from the viewpoint of the world’s financial markets. EvaluatePharma’s forward looking view of the market is hugely influential as it displays the consensus of expectations, which influence company stock market valuations. The forecasts of equity analysts reveal their perspectives on individual company performance, industry trends and the macro economic environment. EvaluatePharma has captured the consensus forecasts of equity analysts and seamlessly integrated them with the historic results, as reported by companies. From this comprehensive view of the industry, its past and expected future performance emerges and can be analysed using EvaluatePharma. Analyses range from total market trends and therapeutic overviews to individual company performance and product progress. Whatever your view on the future of the industry, EvaluatePharma is the essential guide to value in the pharma and biotech sector.
    [Show full text]
  • Download Download
    MENCONI, ORPHAN DRUG INDUSTRY, VOICES IN BIOETHICS, VOL. 5 (2019) Is the Orphan Drug Industry the Proper Scapegoat for Unethical Research Funding? Michael Menconi* Keywords: orphan drugs, cancer, bioethics, pharmaceutical industry INTRODUCTION The mainstream media and general public have expressed frustration in recent months with the confluence of capitalism and the pharmaceutical research and development enterprise. Outrage over arbitrary 1000 percent price hikes for lifesaving drugs like the EpiPen and widespread attribution of moral culpability for the opioid crisis have proven to be enormous outrage-generating controversies for Big Pharma. These headlines amass views, clicks, and social media activism on a massive scale—all portraying pharmaceutical companies as greedy and villainous adversaries. Camouflaged beneath this understandable outrage lies yet another ethically problematic matter, albeit significantly more complicated—the use of federal research dollars, tax incentives, and policy loopholes to study and develop highly specialized “orphan drugs” that benefit a select few while commanding some of the highest prices ever recorded in the history of the pharmaceutical industry. ANALYSIS Federal motivations for stimulating orphan drug development were “beneficent”—to co-opt a popular phrase prevalent in the contemporary bioethics vernacular. Orphan drugs are specifically developed for rare diseases that affect less than 200,000 people. Historically, most pharmaceutical companies avoided researching treatments for rare diseases as sales would be limited to the few patients with the disease, thus impeding profitability. Today, most rare disease research uses federal research dollars in a variety of forms, and the FDA closely coordinates with pharmaceutical companies through its Office of Orphan Products Development (OOPD).1 In order to stimulate orphan drug research, the OOPD offers tax incentives, special patent and marketing rights protections, and clinical research subsidies to pharmaceutical companies willing to undertake orphan drug projects.
    [Show full text]
  • Food and Drug Administration Public Hearing
    FDA Public Meeting: FDA–2010–N–0218 1 7/8/2010 Food and Drug Administration Public Hearing: Considerations Regarding Food and Drug Administration Review and Regulation of Articles for the Treatment of Rare Diseases; Public Hearing Federal Docket Number: FDA–2010–N–0218 Prepared by National Capitol Captioning 200 N. Glebe Road, Ste. 710 (703) 243-9696 Arlington, VA 22203 FDA Public Meeting: FDA–2010–N–0218 2 7/8/2010 Table of Contents Day 1 Meeting Open………......................................…………………………………….3 First Session: National Organization for Rare Disorders………………………………...5 Second Session: Statistical Analysis Center and Mailman School of Public Health….. 11 Third Session: MDJUNCTION.com: Dercum's Disease Support Group………………15 Forth Session: Batten Disease Support and Research Association……………………...18 Fifth Session: Plasma Protein Therapeutics Association……………………………….21 Sixth Session: Rare Disease Advocacy Research Education Sun Valley Pharma Consult, LLC………………………………………24 Seventh Session: Celiac Sprue Association……………………………………………..30 Eighth Session: Kakkis EveryLife Foundation………………………………………….33 Ninth Session: National MPS Society…………………………………………………..39 Tenth Session: Genetic Alliance………………………………………………………...40 Eleventh Session: Lundbeck Inc……………………………………………………….. 42 Twelfth Session: Addison and Cassidy………………………………………………….45 Thirteenth Session: Autoimmunity Research Foundation………………………………51 Fourteenth Session: Dystonia Medical Research Foundation…………………………..57 Day 1 Meeting Close….........................................……………………………………....60
    [Show full text]